Together, we show that the complementaryactivation of TSPO and Kv7.2/3 may offer a novel therapeutic strategyfor ALS/FTD due to its capacity to protect MNs from noncell-autonomoustoxicity induced by diseased astrocytes. Here, TSPO is linked to amyotrophic lateral sclerosis.